公开(公告)号：US20200024319A1

公开(公告)日：2020-01-23

申请号：US15565376

申请日：2016-05-04

Applicant: AMGEN INC. ,  Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Ai Ching LIM ,  Randal Robert KETCHUM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  C07K16/24 ,  A61K38/20 ,  A61P37/00

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20210079051A1

公开(公告)日：2021-03-18

申请号：US17094968

申请日：2020-11-11

Applicant: AMGEN INC.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. ZHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20200010545A1

公开(公告)日：2020-01-09

申请号：US16413810

申请日：2019-05-16

Applicant: AMGEN INC.

Inventor： Zhi LIU ,  Gunasekaran KANNAN ,  Wei YAN

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.

公开(公告)号：US20180319859A1

公开(公告)日：2018-11-08

申请号：US15901705

申请日：2018-02-21

Applicant: Amgen Inc.

Inventor： Marc A. GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua T. PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  C07K16/00 ,  A61K38/00

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

公开(公告)号：US20140161828A1

公开(公告)日：2014-06-12

申请号：US14098275

申请日：2013-12-05

Applicant: Amgen Inc.

Inventor： Richard J. ARMITAGE ,  Michelle BLAKE ,  William C. FANSLOW, III ,  Jason Charles O'NEILL ,  Gunasekaran KANNAN ,  Jiangchun XU ,  Mark Edward TOMETSKO

IPC: A61K47/48 ,  A61K31/537 ,  A61K45/06 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K31/395 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6867 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/18 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

Abstract translation: 本发明涉及BCMA（B细胞成熟抗原）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗疾病的组合物和方法。 本发明还涉及BCMA抗体药物偶联物。

公开(公告)号：US20140024111A1

公开(公告)日：2014-01-23

申请号：US14037040

申请日：2013-09-25

Applicant: AMGEN INC.

Inventor： Gunasekaran KANNAN ,  Michael WITTEKIND ,  Wei YAN ,  Martin J. PENTONY

IPC: C07K16/00

CPC classification number: C07K16/00 ,  A61K38/00 ,  C07K16/468 ,  C07K2317/52 ,  C07K2317/526

Abstract: The invention relates to methods of making Fc-heterodimeric proteins or polypeptides. The invention also relates to the Fc-heterodimeric proteins or polypeptides themselves, including the individual polypeptide components that comprise the heterodimer Nucleic acids encoding such polypeptides, expression vectors, and host cells. Moreover, the invention relates to pharmaceutical compositions comprising one of more Fc-heterodimeric proteins or polypeptides.

Abstract translation: 本发明涉及制备Fc-异二聚体蛋白或多肽的方法。 本发明还涉及Fc-异二聚体蛋白或多肽本身，包括包含编码这种多肽，表达载体和宿主细胞的异二聚体核酸的单个多肽组分。 此外，本发明涉及包含更多Fc-异二聚体蛋白质或多肽之一的药物组合物。

公开(公告)号：US20230128444A1

公开(公告)日：2023-04-27

申请号：US17936062

申请日：2022-09-28

Applicant: AMGEN INC.

Inventor： Hailing HSU ,  Ming ZHANG ,  Gunasekaran KANNAN ,  Frederick W. JACOBSEN ,  Wayne H. TSUJI

IPC: C07K16/46 ,  A61P37/06 ,  A61P19/02 ,  A61P29/02 ,  A61K39/395 ,  C07K16/28 ,  C07K16/18 ,  C07K16/24

Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.

公开(公告)号：US20170183412A1

公开(公告)日：2017-06-29

申请号：US15400800

申请日：2017-01-06

Applicant: Amgen Inc.

Inventor： Yang LI ,  Jennitte LeAnn STEVENS ,  Chadwick Terence KING ,  Ian Nevin FOLTZ ,  Gunasekaran KANNAN ,  Junming YIE ,  Shaw-Fen Sylvia HU

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2319/00 ,  C07K2319/30 ,  C12Y302/01031

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

公开(公告)号：US20160168213A1

公开(公告)日：2016-06-16

申请号：US14908459

申请日：2014-07-31

Applicant: AMGEN INC.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth WALKER

IPC: C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Abstract translation: 提供了包含GDF15的构建体及其突变体。 在各种实施方案中，包含GDF15及其突变体的构建体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。

公开(公告)号：US20160046705A1

公开(公告)日：2016-02-18

申请号：US14443107

申请日：2013-11-21

Applicant: AMGEN INC.

Inventor： Gunasekaran KANNAN ,  Monica FLORIO ,  Zhi LIU ,  Wei YAN

IPC: C07K16/22 ,  C07K16/18

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present application is directed to heterodimeric antibodies and methods of use.

Abstract translation: 本申请涉及异二聚体抗体和使用方法。